Two complementary reports focus on clinical AI’s real-world limits. A scoping review finds infection-surveillance AI is still rarely validated or deployed in live healthcare environments, despite workflow improvements in research settings. Separately, a New England Journal of Medicine analysis is cited suggesting AI-generated care plans may increase costs versus physician-ordered plans, challenging assumptions that automation lowers spending.